Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BridgeBio Pharma (BBIO) Research & Development: 2019-2025

Historic Research & Development for BridgeBio Pharma (BBIO) over the last 7 years, with Sep 2025 value amounting to $112.9 million.

  • BridgeBio Pharma's Research & Development fell 6.29% to $112.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $465.9 million, marking a year-over-year decrease of 7.99%. This contributed to the annual value of $506.5 million for FY2024, which is 11.14% up from last year.
  • Per BridgeBio Pharma's latest filing, its Research & Development stood at $112.9 million for Q3 2025, which was up 1.48% from $111.2 million recorded in Q2 2025.
  • BridgeBio Pharma's Research & Development's 5-year high stood at $141.0 million during Q1 2024, with a 5-year trough of $90.9 million in Q4 2022.
  • In the last 3 years, BridgeBio Pharma's Research & Development had a median value of $114.7 million in 2024 and averaged $118.0 million.
  • As far as peak fluctuations go, BridgeBio Pharma's Research & Development spiked by 79.64% in 2021, and later decreased by 25.61% in 2022.
  • Over the past 5 years, BridgeBio Pharma's Research & Development (Quarterly) stood at $122.2 million in 2021, then decreased by 25.61% to $90.9 million in 2022, then surged by 43.26% to $130.2 million in 2023, then climbed by 0.10% to $130.3 million in 2024, then dropped by 6.29% to $112.9 million in 2025.
  • Its last three reported values are $112.9 million in Q3 2025, $111.2 million for Q2 2025, and $111.4 million during Q1 2025.